On July 21, CME Group declined 3.14% in regular trading, trading at $237.43/share, with turnover of $598 million. The drop came on the eve of the company's quarterly earnings release scheduled for the following day's pre-market session.

On the news front, multiple investment banks issued target price cuts in recent weeks: Rothschild lowered its target from $323 to $303 while maintaining a Buy rating, JPMorgan cut from $273 to $249, Barclays from $316 to $270, UBS from $310 to $260, and Goldman Sachs trimmed to $243 while maintaining a Sell rating. Market consensus expects EPS of $2.92 for the upcoming quarter, a notable sequential decline from last quarter's $3.36. Last quarter, CME reported revenue of $1.88 billion (up 14.48% YoY) and adjusted EPS of $3.36 (up 20% YoY), with net margin at 61.52%.

Additionally, the company recently announced CEO Terry Duffy will step down effective March 1, with CFO Lynne Fitzpatrick named as successor, adding to near-term uncertainty. The stock has declined over 20% from its March highs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)